Avenue Therapeutics is a clinical-stage pharmaceutical company centered on IV Tramadol and related drug candidates, navigating liquidity and regulatory challenges after its Nasdaq delisting in mid-2025. Its latest quarterly filing reveals extended supply agreements, milestone payment obligations totaling $15.6 million for pipeline assets, and a cash position sufficient to cover short-term liabilities. The firm's primary value lies in licensing intellectual property and advancing clinical milestones, with growth contingent on successful FDA approvals and strategic partnerships. Trading on the OTC Pink market introduces heightened stock volatility and liquidity risks that could impact financing options.